other_material
confidence high
sentiment positive
materiality 0.75
Fractyl Health: Revita shows 92% weight maintenance post-GLP-1; Rejuva prevents obesity in mice
FRACTYL HEALTH, INC.
- 12 of 13 Revita participants maintained or lost weight at 3 months after stopping GLP-1; median weight stable (0.46% change).
- No serious adverse events with Revita; REMAIN-1 Midpoint cohort data expected Q3 2025 and Pivotal cohort H2 2026.
- Rejuva single dose prevented obesity and hyperglycemia in high-fat diet mice; 20% weight reduction and 38% glucose decrease.
- Rejuva RJVA-001 progressing toward first-in-human studies; preliminary clinical data anticipated in 2026.
item 7.01item 8.01item 9.01